Authors : Dr. Asama Sayyad; Dr. Fouad Kadhim Gatea

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/5bf32u8c

Scribd : https://tinyurl.com/36swnf4w

DOI : https://doi.org/10.38124/ijisrt/26May1248

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age worldwide. It is associated with menstrual irregularities, hyperandrogenism, infertility, obesity, insulin resistance, and metabolic disturbances. Combined oral contraceptives (COCs) remain the first-line pharmacological treatment for menstrual regulation and androgen suppression in women not seeking pregnancy. Recently, interest has increased in herbal therapies such as alfalfa due to their antioxidant, anti-inflammatory, phytoestrogenic, and metabolic effects. This review evaluates the therapeutic impacts of alfalfa, COCs, and the combination of both in the management of PCOS. Available evidence suggests that COCs effectively regulate menstruation and reduce androgenic symptoms, while alfalfa may improve metabolic parameters and oxidative stress. Combination therapy may provide synergistic benefits by targeting both hormonal imbalance and metabolic dysfunction. However, clinical evidence regarding alfalfa in PCOS remains limited, and further randomized controlled trials are required to establish safety, efficacy, and long-term outcomes.

Keywords : Polycystic Ovary Syndrome; Alfalfa; Combined Oral Contraceptives; Herbal Therapy; Hyperandrogenism; Infertility.

References :

1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
2. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-18.
3. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84.
4. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome. J Clin Endocrinol Metab. 2016;101(11):3727-35.
5. Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575-92.
6. Medenica S, Nedeljkovic O, Radojevic N, Stojkovic M, Trbojevic B. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Med Pregl. 2015;68(9-10):300-5.
7. Bora KS, Sharma A. Phytochemical and pharmacological potential of Medicago sativa: a review. Pharm Biol. 2011;49(2):211-20.
8. Eddouks M, Maghrani M, Zeggwagh NA, Michel JB. Study of the hypoglycaemic activity of Medicago sativa. J Ethnopharmacol. 2005;99(3):391-5.
9. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia and hyperandrogenemia. Fertil Steril. 1994;61(3):392-5.
10. Ibrahim RM, Hamdan FB. Oxidative stress and antioxidant status in Iraqi women with polycystic ovary syndrome. Iraqi J Med Sci. 2019;17(2):95-101.